Details

Autor(en) / Beteiligte

• Rajwa, Pawel
• Borkowetz, Angelika
• Abbott, Thomas
• Alberti, Andrea
• Bjartell, Anders
• Brash, James T.
• Campi, Riccardo
• Chilelli, Andrew
• Conover, Mitchell
• Constantinovici, Niculae
• Davies, Eleanor
• De Meulder, Bertrand
• Eid, Sherrine
• Gacci, Mauro
• Golozar, Asieh
• Hafeez, Haroon
• Haque, Samiul
• Hijazy, Ayman
• Hulsen, Tim
• Josefsson, Andreas
• Khalid, Sara
• Kolde, Raivo
• Kotik, Daniel
• Kurki, Samu
• Lambrecht, Mark
• Leung, Chi-Ho
• Moreno, Julia
• Nicoletti, Rossella
• Nieboer, Daan
• Oja, Marek
• Palanisamy, Soundarya
• Prinsen, Peter
• Reich, Christian
• Raffaele Resta, Giulio
• Ribal, Maria J.
• Gómez Rivas, Juan
• Smith, Emma
• Snijder, Robert
• Steinbeisser, Carl
• Vandenberghe, Frederik
• Cornford, Philip
• Evans-Axelsson, Susan
• N'Dow, James
• Willemse, Peter-Paul M.

Titel

Research Protocol for an Observational Health Data Analysis on the Adverse Events of Systemic Treatment in Patients with Metastatic Hormone-sensitive Prostate Cancer: Big Data Analytics Using the PIONEER Platform

Ist Teil von

• European urology open science (Online), 2024-05, Vol.63, p.81-88

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2024

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Despite their efficacy, novel combination systemic therapies for metastatic hormone-sensitive prostate cancer (mHSPC) are associated with side effects. Our study reports drug-related adverse events in a large cohort of “real-life” patients treated with combination therapies for mHSPC. Combination therapies in metastatic hormone-sensitive prostate cancer (mHSPC), which include the addition of an androgen receptor signaling inhibitor and/or docetaxel to androgen deprivation therapy, have been a game changer in the management of this disease stage. However, these therapies come with their fair share of toxicities and side effects. The goal of this observational study is to report drug-related adverse events (AEs), which are correlated with systemic combination therapies for mHSPC. Determining the optimal treatment option requires large cohorts to estimate the tolerability and AEs of these combination therapies in “real-life” patients with mHSPC, as provided in this study. We use a network of databases that includes population-based registries, electronic health records, and insurance claims, containing the overall target population and subgroups of patients defined by unique certain characteristics, demographics, and comorbidities, to compute the incidence of common AEs associated with systemic therapies in the setting of mHSPC. These data sources are standardised using the Observational Medical Outcomes Partnership Common Data Model. We perform the descriptive statistics as well as calculate the AE incidence rate separately for each treatment group, stratified by age groups and index year. The time until the first event is estimated using the Kaplan-Meier method within each age group. In the case of episodic events, the anticipated mean cumulative counts of events are calculated. Our study will allow clinicians to tailor optimal therapies for mHSPC patients, and they will serve as a basis for comparative method studies.